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Abstract: To develop a carrier for use in enzyme prodrug therapy, Horseradish peroxidase 
(HRP) was immobilized onto mesoporous silica nanoparticles (IBN-4: Institute of 
Bioengineering and Nanotechnology), where the nanoparticle surfaces were functionalized 
with 3-aminopropyltrimethoxysilane and further conjugated with glutaraldehyde. 
Consequently, the enzymes could be stabilized in nanochannels through the formation of 
covalent imine bonds. This strategy was used to protect HRP from immune exclusion, 
degradation and denaturation under biological conditions. Furthermore, immobilization of 
HRP in the nanochannels of IBN-4 nanomaterials exhibited good functional stability upon 
repetitive use and long-term storage (60 days) at 4 °C. The generation of functionalized 
and HRP-immobilized nanomaterials was further verified using various characterization 
techniques. The possibility of using HRP-encapsulated IBN-4 materials in prodrug cancer 
therapy was also demonstrated by evaluating their ability to convert a prodrug (indole-3- 
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acetic acid (IAA)) into cytotoxic radicals, which triggered tumor cell apoptosis in human 
colon carcinoma (HT-29 cell line) cells. A lactate dehydrogenase (LDH) assay revealed 
that cells could be exposed to the IBN-4 nanocomposites without damaging their 
membranes, confirming apoptotic cell death. In summary, we demonstrated the potential of 
utilizing large porous mesoporous silica nanomaterials (IBN-4) as enzyme carriers for 
prodrug therapy. 
Keywords: mesoporous silica nanoparticles; enzyme immobilization; Institute of 
Bioengineering and Nanotechnology (IBN-4); anti-cancer; prodrug therapy 
 
1. Introduction 
The delivery of fragile drugs to target sites at precise times and locations with high drug activity in  
a reproducible manner is an outstanding challenge. Various delivery approaches have been developed  
to create effective therapeutic methods to target cancerous sites using a variety of versatile drug 
formulations. The magic of bioactivation is that the therapeutic method acts by specifically activating 
the prodrug into active drug molecules upon reaching the targeting site. The prodrug approach was 
developed by Albert in 1958 for the purposes of increasing therapeutic efficacy and reducing cytotoxic 
side effects through the activation of toxic drugs at targeted sites. A prodrug is defined as a nontoxic 
precursor of an active drug that can be transformed into the active drug molecule by enzymatic 
catalysis and consequently deliver therapeutic effects to targeted sites. Enzyme prodrug therapy (EPT) 
is a novel therapeutic approach where prodrug-activating enzymes are initially delivered into the 
cancer cells using various targeting approaches; this enzyme delivery is followed by treatment with a 
nontoxic prodrug that is specifically activated into an anticancer drug through the enzymatic activity in 
the targeted cells. The concentration of the activated drug can be high in the tumor sites, thereby 
reducing systemic toxicity in normal tissues [1–5]. Hence, this therapeutic method can be applied to 
improve tumor targeting while reducing systemic toxicity. For the successful use of EPT in clinical 
applications, the catalytic enzymes in normal tissues that activate the prodrugs must be present at 
lower concentrations than in cancer tissues [6,7]. In recent years, EPT has been examined as a potential 
strategy for treating devastating diseases such as cancer [8–10]. The development of an efficient 
enzymatic delivery vehicle that can carry and activate prodrug molecules and kill cancer cells is extremely 
important. Many approaches have been developed to deliver various enzymes for the activation of 
anticancer prodrugs, such as antibodies, viruses, lectins, spores and liposomes [11–19]. Despite some of 
the advantages associated with these approaches, the sole use of antibodies and lectins is hindered by 
their poor bioavailability [20], whereas the scope of possible pathogenicity hampers the use of 
microbial vectors. However, the use of immunoliposomes has been shown to enhance enzymatic 
delivery compared to the sole use of antibody-enzyme conjugates [21,22], which has gained 
considerable attention with regards to nanoparticle-based drug delivery systems. Motivated by the 
advantages of immunoliposomes observed in drug delivery, many researchers have used liposomal, 
polymeric and other organic nanoparticle-based systems for prodrug therapy [23–27]. Nevertheless, 
liposomes and other organic nanoparticles have also been shown to have certain drawbacks, such as 
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low encapsulation efficiencies, rapid leakage of water-soluble molecules, susceptibility to microbial 
attack in the presence of blood components and poor storage stabilities; these drawbacks may limit the 
application of liposomes in prodrug therapy [28]. 
In the last decade, exceptional developments have been made with respect to inorganic nanoparticles 
in the field of drug delivery. Researchers have developed various prodrugs for targeted delivery using a 
wide range of inorganic nanocomposites [17,29–32]. Many inorganic nanomaterials such as gold [33], 
silver, magnetic-Fe/Fe3O4 [34], gold-coated super paramagnetic iron oxide [35], carbon nanotubes, 
mesoporous silica [36,37], and layered double hydroxide (LDH) nanoparticles [38,39] have gained much 
attention due to their novel multifaceted characteristics that include low cytotoxicities, high loading 
capacities, large surface to volume ratios, good stabilities, rich functionalities, biocompatibilities, and 
targeting abilities; consequently, these types of inorganic nanomaterials are considered to be ideal 
enzyme carriers for various biological applications. 
Many breakthroughs have been made for the loading of bioactive molecules such as enzymes placed 
in the tunable pores of mesoporous silica and great improvements in cellular uptake efficiencies [40,41]. 
Very recently, phosphonate@mesoporous silica nanoparticles (MSNs) were synthesized for the 
intracellular delivery of fluorescein-labeled bovine serum albumin (BSA) cargo using the folate 
receptor pathway; these MSNs were shown to have potential for use in targeted drug delivery for the 
treatment of cancer [42]. Sun et al. reported the development of gold nanoparticle-capped MSNs 
loaded with luciferase to retain enzyme bioactivity through intracellular-controlled catalysis and their 
use in tumor imaging. This provides a unique platform for monitoring metastasis by means of 
bioluminescence and using intracellular ATP and GSH levels as indicators [43]. Mou et al. proposed a 
new strategy for the intracellular delivery of superoxide dismutase, where multi-functional MSN 
nanocontainers were used to enhance the transmembrane permeability of the enzyme. This therapy was 
successful in delivering protein treatment for ROS-mediated diseases [44]. Interestingly, a variety of 
enzymes were immobilized in the mesoporous silica spheres in high loads, with safeguards to maintain 
stability [45–48], and the enzymes were shown to retain their bioactivities [41,49,50]. 
For the successful exploitation of EPT in treating cancer, it is a crucial to maintain therapeutic 
levels of the enzymes for catalytic activity at the tumor sites; simultaneously, the prodrug must be able 
to cross the cell membranes for successful prodrug activation. To meet these criteria, there is a need to 
employ safe delivery vehicles to protect the enzymes from biological stress and to retain their catalytic 
activity. Furthermore, the carriers must be able to selectively transport the enzymes to the desired sites 
after crossing the cellular membranes to maintain therapeutic levels of the prodrug and the enzyme 
even after prolonged circulation times. These outstanding and largely unmet challenges are best 
addressed by MSNs (Figure 1). The immobilization of enzymes in MSNs for use in EPT is one of the 
most promising developments in cancer therapy. MSNs have many advantages including high 
biocompatibility, easy biodegradation and metabolism, controllable particle and pore sizes [51–56], 
large surface areas [57], and an abundance of sites available for surface functionalization, which render 
them the most preferable enzyme delivery vehicle to date [58]. Earlier studies have shown that 
immobilization of enzymes in mesoporous silica are less susceptible to damage caused by changes in 
pH and temperature and interactions with organic solvents [46,59–62]. Enzymes can be safely 
transported to target sites by encapsulation in the nanochannels of mesoporous silica; the scope of 
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these vehicles with regards to targeting tumor cells can be expanded by attaching various types of 
ligands (e.g., antibodies, peptides, aptamers, and vitamins) to the surface of the MSNs [63,64]. 
 
Figure 1. Schematic representation of enzyme prodrug therapy using IBN-4-HRP 
nanocomposites in the presence of indole-3-acetic acid and the resultant cell apoptosis  
(1. Skatolyl radical and 2. Peroxyl radical). 
2. Results and Discussion 
A schematic illustration for the synthesis of enzyme-immobilized MSNs is shown in Figure 1.  
The purpose of our study was to immobilize HRP onto IBN-4 nanoparticles via covalent linkages  
to facilitate the activation of the prodrug IAA (indole acetic acid) in the tumor microenvironment. 
Pristine IBN-4 nanoparticles were synthesized using a template (Pluronic P123) and an FC-4 
nanoparticle overgrowth protectant (fluorocarbon surfactant). Hydrolysis and condensation of 
tetraethoxysilane (TEOS) were performed under dilute acidic conditions. The surfactant was then 
removed by oxidation with ammonium perchlorate and a 10 M HNO3 solution; the resulting sample was 
labelled “IBN-4-extracted”. After oxidation under acidic conditions, the surfaces had large amounts of 
silanol groups, which were easily functionalized with 3-aminopropyltrimethoxysilane (APTS) to afford 
the amine-modified mesoporous silica surfaces (IBN-4-NH2). Subsequent conjugation of glutaraldehyde 
(GA) (IBN-4-NH-GA) allowed the aldehyde to serve as an anchor for the successful immobilization of 
enzymes on the surface of the silica particles through the formation of imine bonds (IBN-4-HRP). The 
reaction between IAA and HRP proceeded through a complex mechanism where IAA was activated by 
HRP and produced free radicals (Figure 1), such as indolyl, skatolyl, and peroxyl radicals, and reactive 
oxygen species (ROS), such as ·O2− and H2O2. These reactive molecules caused morphological 
changes of the cells and initiated damage by inducing apoptotic-signaling cascades [65]. Thus, the 
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proposed IAA/HRP combination may have enhanced cellular oxidative stress and may have led to cell 
death. Nanoparticle size and enzyme stability play a key role in the interaction and activation of 
prodrug molecules in cells during EPT. First, nanoparticles within a range of <300 nm were shown to 
have good dispersion, escape uptake by the reticuloendothelial system (RES) and enhance the EPR 
(Enhanced permeability and retention) effect [66–68]. However, recent research has shown that 
nanoparticles less than 100 nm in size could result in severe cytotoxicity due to nonspecific cellular 
interactions [69–71]. Therefore, in the current investigations, we employed IBN-4 nanoparticles that 
had a mean diameter that was greater than 100 nm, as shown in Figure 2. It was evident from the 
Transmission electron microscopic (TEM) images that the particles exhibited an average particle 
diameter of approximately 150–300 nm with aspect ratios (length to the width dimension ratio of 
uniformly sized nanoparticles) in the range of approximately 4 to 6. The morphology and particle size 
of IBN-4 did not change after the amine modification process (Figure 2c) and subsequent conjugation 
of HRP (Figure 2d). In addition, the DLS measurements (particle diameter and zeta potential) were 
recorded and are illustrated in Table 1. The particle sizes of all of the samples were nearly in accord 
with observations from the TEM images; however, a small amount of aggregation was observed in the 
case of IBN-4-HRP, which resulted in aggregates sizes of ~390 nm. Previous reports suggest that 
particles with an average particle size of <300 nm should be favorable due to ease of internalization 
considering the EPR effect [66,56]. The zeta values of pristine IBN-4 and IBN-4 extracted were −0.1 
and −10.9 mV, respectively. IBN-4-HRP exhibited a negative shift in surface charge (i.e., +17.7 mV) 
compared to IBN-4-NH2 (i.e., +26.3 mV). The positive zeta potential of enzyme-loaded IBN-4 
nanoparticles facilitated cellular internalization through negatively charged cell membranes during 
biological investigations. 
 
Figure 2. Transmission electron microscopic images of IBN-4 nanoparticles: (a) As-synthesized 
IBN-4,  (b) IBN-4-extracted, (c) IBN-4-NH2, and (d) IBN-4-HRP. 








Particle Size * 
(nm) 
Zeta Potential * 
(mV) 
Pristine IBN-4 345 7.9 0.75 271 (±3.0) −0.1 (±0.1) 
IBN-4 extracted 812 9.3 1.71 254 (±7.6) −10.9 (±0.4) 
IBN-4-NH2 357 6.0 0.98 296 (±6.4) +26.3 (±0.7) 
IBN-4-HRP 296 6.5 1.1 394 (±9.5) +17.7 (±0.2) 
* Values in parenthesis represent the standard deviation for the respective mean value. 
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The mesoporous characteristics of IBN-4 nanoparticles were determined using N2-adsorption/desorption 
isotherms and BET theory with an ASAP 2020 Micromeritics surface area analyzer at −196 °C (Figure 3A, 
Table 1). The pore size distributions of pristine IBN-4, IBN-4 nanoparticles after surfactant removal 
(IBN-4-extracted), IBN-4 nanoparticles modified with APTS groups (IBN-4-NH2) and glutaraldehyde 
conjugation nanoparticles for immobilization of HRP (IBN-4-HRP) were determined from adsorption 
branches of the isotherms using the Barrett–Joyner–Halenda (BJH) method (inset of Figure 3A). There 
was a significant increase in the specific surface areas and pore volumes of the nanoparticles after 
surfactant removal from as-synthesized IBN-4 (345 m2·g−1, 0.75 cm3·g−1) (Figure 3A(a)) to 812 m2·g−1 
and 1.71 cm3·g−1, respectively (Figure 3A(b)). Later, the final BET surface areas of the IBN-4- 
extracted sample decreased from 812 to 357 m2·g−1 and the pore volumes decreased from 1.71 cm3·g−1 
to 0.98 cm3·g−1 after amine modification (Figure 3A(c)). These changes were sufficient for the 
conjugation of enzymes in the mesoporous channels. Furthermore, the immobilization of the HRP 
enzyme (Figure 3A(d)) through a glutaraldehyde anchor decreased the surface area to 296 m2·g−1, but 
the pore volume was increased to 1.1 cm3·g−1 due to the contributions of enzyme molecules to the 
porosity of the particles. In addition, the area and intensity of the pore size distribution near 6.0 nm 

































































































Figure 3. (A) Nitrogen adsorption–desorption isotherms of (a) as-synthesized IBN-4,  
(b) IBN-4 extracted, (c) IBN-4-NH2 and (d) IBN-4-HRP. Corresponding pore size 
distribution plots are shown in the inset figure. (B) Thermogravimetric analysis curves of 
(a) as-synthesized IBN-4; (b) IBN-4 extracted, (c) IBN-4-NH2, (d) IBN-4-NH-GA and  
(e) IBN-4-HRP. 
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Thermogravimetric (TGA) curves of all of the samples were recorded and the successive weight 
loss events were analyzed, as illustrated in Figure 3B. The primary weight loss (i.e., 5%–8%) below 
100 °C was attributed to loss of physisorbed moisture of the sample (Figure 3B(a)–(e)). The weight 
loss observed at 350 °C was due to surfactant decomposition in the as-synthesized sample  
(Figures 3B(a)) and the same observation was made for the IBN-4 sample extracted with ammonium 
perchlorate (Figure 3B(b)), which revealed the complete extraction of the surfactant. Similarly, a broad 
decomposition band centered at 362 °C was due to weight loss (i.e., ~16%) from decomposition of the 
surface functionalized APTS. Furthermore, conjugation of glutaraldehyde to the surface amine resulted 
in decomposition at 180, 265 (i.e., ~12%) and 580 °C. This confirmed the effective conjugation of the 
glutaraldehyde spacer for immobilization of HRP. The final events in the HRP-immobilized samples 
(IBN-4-HRP (Figure 3B(e)) resulted in weight loss in the range of 400–500 °C, demonstrating the 
effective immobilization of the enzymes (HRP weight loss alone i.e., ~14%) that completely occupied 
the active aldehyde groups. It was detrimental for any of the aldehyde groups to remain free because 
glutaraldehyde exists as a low molecular weight polymer when it is used as spacer for protein 
immobilization. Thus, researchers should be quite cautious when using glutaraldehyde as a spacer. The 
amount of HRP weight loss from IBN-4 was approximately the same as the loading percentage 
obtained from ultraviolet-visible (UV-Vis) spectroscopy using a Bio-Rad enzyme quantification 
assay (IBN-4-HRP (13.13%)). 
Fourier transform infrared spectroscopy (FT-IR) was performed to characterize the chemical 
modifications of the IBN-4 samples and their post-synthetic conjugations. The spectra of the  
as-synthesized and surfactant extracted IBN-4 samples are displayed in Figure 4. The bands at 1080 
and 460 cm−1 confirms the Si-O-Si framework in all of the samples. Additionally, the typical bands 
observed at approximately 2900–3200 cm−1 were attributed to the asymmetric stretching vibrations of 
C-H in the aliphatic moieties of the surfactant. These bands vanished after oxidative extraction  
(Figure 4b), in contrast to those observed in Figure 4a, which confirmed that the surfactant was 
completely removed. However, the peaks of the Si–O–Si framework remained, which confirmed that 
the framework was not destroyed under oxidative reaction conditions. The C–H stretching bands at 
2973 cm−1 and 2933 cm−1 appeared in the spectra of the amine functionalized IBN-4 samples  
(Figure 4c). The glutaraldehyde-conjugated IBN-4 displayed C=O (an aldehyde) stretching modes at 
or near 1667 cm−1 (Figure 4d). The spectrum of the HRP-loaded nanocarrier resulted in amide bands at 
1452 and 1550 cm−1. In addition, the band at 1550 cm−1 represented the NH bending vibrations in the 
plane; the intensity of the peak at 1452 was much lower than before [72]. Thus, the FT-IR spectra 
indicated the sequential modifications of IBN-4 were successful. 
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Figure 4. Fourier transform infrared spectroscopy (FT-IR) spectra of the (a) as-synthesized 
IBN-4 nanoparticles, (b) IBN-4 nanoparticles after surfactant removal (IBN-4-extracted), 
(c) IBN-4 nanoparticles modified with APTS groups (IBN-4-NH2), (d) IBN-4-NH2 
nanoparticles modified with glutaraldehyde groups (IBN-4-NH-GA) and (e) IBN-4-NH- 
GA nanoparticles immobilized with HRP (IBN-4-HRP). 
2.1. Detection of Primary Amine Groups 
The amino groups on the surface functionalized IBN-4 samples were quantitatively analyzed using 
UV-Vis spectrometry after treating the samples with ninhydrin to yield Ruhemann’s purple coloration 
that displayed an absorption band at 580 nm upon reaction with primary amines. Unmodified IBN-4 
nanoparticles (Figure 5b) did not show any prominent peaks at 580 nm due to the absence of amine 
groups. However, IBN-4-NH2 samples exhibited a characteristic band at 580 nm (Figure 5c) along 
with the production of Ruhemann’s purple, as shown in the respective inset sample images. This 
phenomenon indicated that large amounts of amino groups were conjugated to the surfaces of the  
IBN-4 samples. Glutaraldehyde-conjugated IBN-4-NH2 nanomaterials (Figure 5d) showed very low 
absorption values for the active amine groups as confirmed by the lower absorption peaks at 580 nm; 
this observation could be explained by the reaction of the two terminal amino groups with 
glutaraldehyde moieties and their subsequent transformations into secondary amines. 
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Figure 5. Ultraviolet–visible (UV-Vis) spectra and white-light sample images (inset) of  
(a) ninhydrin alone, (b) IBN-4 nanoparticles after surfactant removal, (c) IBN-4 
nanoparticles modified with APTS groups (IBN-4-NH2) and (d) IBN-4 nanoparticles 
modified with glutaraldehyde groups (IBN-4-NH-GA). 
2.2. Properties of Immobilized HRP 
The specific activities per unit weight of enzymes for the HRP-immobilized nanoparticles were  
solely dependent on the method employed to immobilize the HRP molecules. We loaded HRP 
molecules using a typical two-step method (IBN-4-HRP) and utilized a one-pot synthetic approach 
(IBN-4-HRP (one pot)) to compare the resulting enzyme activities. The efficacies of delivery and the 
anti-tumor activities of the two methods were successfully compared. It was evident that enzyme 
immobilization onto IBN-4 nanomaterials using a two-step process (IBN-4-HRP (4144 units/g)) 
resulted in significantly higher yields than when the one pot approach was used (IBN-4-HRP (one 
pot)) (953.60 units/g)). The low enzymatic activities of the nanoparticles immobilized using the  
one-pot approach were attributed to the reaction between the amino groups of HRP and glutaraldehyde 
molecules, which formed undesirable enzyme complexes; these complexes may have caused the active 
sites to denature through saturation of lysine residues. These undesirable enzyme-bound complexes 
could be removed by washing steps, which limited enzyme loading in the functionalized IBN-4 
nanoparticles. Consequently, this led to lower loading amounts with the one-pot synthetic approach 
(IBN-4-HRP (one pot i.e., 9.87%) compared to IBN-4-HRP (two-step process i.e., 13.13%)), as 
observed by UV-Vis spectroscopy with a Bio-Rad enzyme quantification assay. The long-term 
stability (stored at 4 °C) and the activity of HRP immobilized IBN-4 nanoparticles were also 
evaluated. Interestingly, over 90% of the original peroxidase activity of HRP was retained after two 
months. These results revealed that the stability of the HRP entrapped in IBN-4 increased without 
losing biological activity. 
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2.3. IAA-Dependent Cytotoxicity of HRP Encapsulated IBN-4 
The cytotoxic effects of using HRP-loaded IBN-4 in EPT were explored using an MTT  
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay with a HT-29 (Human colon 
carcinoma) cell line (Figure 6), and the morphological changes were simultaneously observed using 
bright field microscopy (Figure 7). Previously, it was reported that the uptake of silica nanoparticles 
was fairly rapid and was observed after 2–3 h, with toxicity generally observed within 24 h [73]. To 
exclude the possible influence of enzyme-loaded nanoparticles on cell viability, various concentrations 
of HRP-loaded IBN-4 materials prepared using two synthetic routes were incubated for 24 h and the 
cell viability was evaluated. The tested concentration range was as high as 500 μg/mL, and the 
enzyme-loaded IBN-4 materials had no ostensible adverse effects on cell viability (Figure 6A). This 
demonstrated that the enzyme-loaded nanoparticles had no substantial cytotoxicity. Furthermore, the 
incubation of HT-29 cells with IAA alone did not show any signs of toxicity and, surprisingly, 90% of 
the cells were viable even at a concentration of 1000 μM (Figure 6B). 
 
 
Figure 6. Cont. 
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Figure 6. The viability of Human colon carcinoma (HT-29) cells: (A) treatment with  
IBN-4 loaded with Horseradish peroxidase (HRP) prepared via two synthetic routes;  
(B) treatment of IBN-4-HRP synthesized using two different routes in the presence or 
absence of indole-3-acetic acid (IAA) (IAA expressed in µM); and (C) treatment of 
various concentrations (200 and 500 μg/mL) of IBN-4-HRP synthesized in the presence or 
absence of IAA (IAA expressed in µM). 
 
Figure 7. Bright field images of HT-29 cells without or with treatment of HRP-loaded  
IBN-4 nanoparticles and IAA: (a) Control (cells without treatment), (b) treatment with 
IAA (500 μM), (c) treatment with IAA (500 μM) and IBN-4-HRP (one-pot) (100 μg/mL) 
and (d) treatment with IAA (500 μM) and IBN-4-HRP (100 μg/mL). 
However, when IAA was combined with enzyme-loaded IBN-4, it became toxic to HT-29 cells 
(Figure 6B). Cell growth inhibition was observed to be 35% in IBN-4-HRP (one pot) (100 μg/mL) at 
100 μM, whereas 70% of cell death was observed when the concentration of IAA was increased to  
500 μM. A very similar dose-dependent cytotoxic pattern was observed in cells treated with IBN-4- 
HRP in combination with IAA. Nevertheless, the activity of the enzymes immobilized with the one-pot 
approach showed significantly higher activity than the particles immobilized with the typical two-step 
approach at lower concentrations; at higher concentrations, both samples exhibited nearly identical 
cytotoxic effects. This contrast in enzyme activity and cytotoxicity with respect to different synthetic 
approaches may have been due to the enzyme release characteristics during the prodrug activation 
process. Similarly, when treatment was continued at higher concentrations of IBN-4-HRP (200 and  
500 μg/mL) (Figure 6C) in the presence of IAA (0–1000 μM), increases in the nanoparticle–enzyme 
complex concentration did not result in further changes in activity. This demonstrated that the enzyme 
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prodrug therapy exclusively depends on the concentration of the prodrug and that the respective 
concentration (from 100 to 500 μg/mL) is suitable for activation of the prodrug. 
The morphological changes of the HT-29 cells incubated with enzyme-loaded IBN-4 nanoparticles 
and IAA were also studied using bright field microscopy (Figure 7). HT-29 cells treated with  
enzyme-loaded IBN-4 nanomaterials (100 μg/mL) and IAA (500 μM) exhibited nuclear condensation 
and substantially shrunken morphologies (Figure 7c,d), suggesting the induction of apoptosis. No 
morphological changes were observed in cells treated with either IAA alone (Figure 7b) or with the 
untreated control (Figure 7a). These results were in accordance with observations from the cytotoxicity 
study and indicated that the enzyme-loaded IBN-4 materials have the potential to replace free-HRP in 
enzyme-prodrug cancer therapy. 
We used a lactate dehydrogenase (LDH) assay to measure the activity of the LDH enzyme that was 
released through cell membrane damage. For this experiment, maximum release of the positive control 
was obtained by treating the cells with 0.5% triton X-100 (Figure 8). Compared with the control 
experiment (CTL), treatment with IAA, (1.6 mM) enzyme-loaded IBN-4 materials, or a combination 
of the two did not result in a profound increase in the release of LDH even at doses as high as  
100 μg/mL. From the results obtained, it was concluded that enzyme-loaded IBN-4 generated with 
either of the routes was highly biocompatible and retained membrane integrity by decreasing the 
amount of unexpected necrotic cell death. The majority of the anti-cancer drugs induce cell death 
through apoptotic or necrotic pathways. Induction of cell death by the apoptotic pathway confers many 
advantages over the necrotic pathway because the leakage of enzymes that results from the necrosis 
pathway usually causes an inflammatory response, which results in poor prognosis in cancer therapy. 
Furthermore, we analyzed the morphological changes of the HT-29 cells incubated with HRP-loaded 
IBN-4 and IAA by bright field microscopy (Figure 9). After treating the cells with IBN-4-HRP and IAA 
(1.6 mM), the morphologies of the cells became round and shrunk, which is a typical phenomenon 
observed for cell apoptosis. In comparison with the groups treated with IAA or IBN-4-HRP alone, the 
cell morphologies rarely had round shapes or shrunk, which demonstrates the low cytotoxicities of the 
individual treatment methods. 
 
Figure 8. Cytotoxic estimates of IBN-4 nanocomposites using an lactate dehydrogenase 
(LDH) leakage assay. Control experiment (CTL), P represents positive control (treated with 
Triton x-100) with various treatments using combinations of IAA and IBN-4-HRP. 
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Figure 9. Bright field images of HT-29 cells with or without treatment of IBN-4-HRP and 
IAA: (a) HT-29 cells without treatment; (b) treatment with IAA (1.6 mM); (c) treatment 
with IBN-4-HRP alone; and (d) treatment with IBN-4-HRP and IAA (1.6 mM). 
Previous reports have suggested that the combination of IAA and HRP can induce apoptosis  
by activating p38 mitogen-activated protein (MAP) kinase and c-Jun N-terminal kinase (JNK). 
Furthermore, this combination was shown to activate caspase-8 and caspase-9 and to induce DNA 
damage [74]. To elucidate the mechanism of cell death, the DNA damage was investigated using a 
comet assay. Comet assays have been considered to be a very good technique for determining DNA 
damage and has been shown to have many advantages over existing methods that measure DNA 
fragmentation. The results of the comet assay showed significant DNA damage, which was indicated 
by the tail moment (Figure 10d) after treatment with enzyme loaded-IBN-4 materials (IBN-4-HRP) in 
the presence of IAA. Furthermore, the bright field images revealed profoundly shrunken cell 
morphologies when enzyme-loaded nanomaterials (IBN-4-HRP) were incubated along with IAA  
(500 μM) (Figure 10c), suggesting the induction of apoptosis. No morphological changes were 
observed in the control group (Figure 10a). 
 
Figure 10. Microphotographs of bright field and fluorescent microscopic views of HT-29 
cells: (a) Bright field view of untreated control cells (undamaged cells); (b) fluorescent 
microscopic view of untreated control cells (undamaged cells); (c) bright field view of cells 
treated with IAA (1 mM) and IBN-4-HRP (100 μg/mL) (shrunken morphologies); and  
(d) fluorescent microscopic view of cells IAA (1 mM) and IBN-4-HRP (100 μg/mL) 
(damaged cells with elongated tails). 
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3. Experimental Section 
3.1. Materials 
Pluronic P123, tetraethyl orthosilicate (TEOS), ammonium perchlorate (AP), (3-aminopropyl)trimethoxysilane 
(APTS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), potassium bromide 
(KBr) (FT-IR grade), glutaraldehyde (GA), horseradish peroxidase (HRP) and 3-indole acetic acid 
(IAA) were purchased from Sigma-Aldrich® (St. Louis, MO, USA). All other reagents and chemicals 
were analytical grade materials. 
3.2. Characterization and Instruments 
TEM images were captured on a Hitachi H-7100 (Hitachi High Technologies Corporation, Tokyo, 
Japan) instrument operating at 100 kV. Samples were prepared by dispersing them on carbon-coated 
copper (Cu) grids and drying them at room temperature. Fluorescence images were captured on an 
Olympus microscope hybridized with cooled color CCD of an Olympus DP73 (Olympus Corporation, 
Center Valley, PA, USA). The centrifuge used for nanomaterial syntheses and cell culturing processes 
at appropriate temperatures and rpm was an Hermle Z 36 HK (HERMLE Labortechnik GmbH, 
Wehingen, Germany) and a swing rotor Kubota KN-70 (Kubota Corporation, Tokyo, Japan), 
respectively. Thermogravimetric analyses were performed using a TGA Q50 V20, 13 Build 39 
(Universal V4.5A TA Instruments, Lukens drive,  New Castle, PA, USA). Dynamic light scattering 
(DLS) measurements to determine particle sizes and zeta potentials were performed using a Nano-HT 
Zetasizer 90 (Malvern Instruments Ltd., Worcestershire, UK). Ultraviolet-visible (UV-Vis) spectra 
were recorded on a Genequant-1300 series spectrophotometer (GE Healthcare Biosciences, Pittsburgh, 
PA, USA). MTT absorbance was recorded using an EnSpire Multi-label Plate Reader (Perkin Elmer, 
Santa Clara, CA, USA). 
3.3. Synthesis of IBN-4 Type Mesoporous Silica Nanoparticles 
IBN-4 type mesoporous silica nanoparticles were prepared by following a previously published 
method [75], where 1 g of pluronic acid P123 and 2.8 g of FC-4 (C3F7O(CFCF3CF2O)2CFCF3 
CONH(CH2)3N+(C2H5)2CH3I−) were dissolved in 160 mL of 0.02 M HCl at 45 °C. After complete 
dissolution of the surfactant, TEOS (4 g) was added and the reaction mixture was stirred at room 
temperature for 20 h. The pristine IBN-4 particles were collected by centrifugation at 12,000 rpm for 
17 min, and the copolymer templates were further removed by ammonium perchlorate (AP) [76]. To 
create oxidative conditions, approximately 0.2 g of the IBN-4 solids was treated with 0.4 g of AP in 20 
mL of a 10 M HNO3 solution under 100 °C for 12 h. The solid products were washed with dd-H2O and 
collected by centrifugation at 12,000 rpm for 17 min. 
3.4. Synthesis of Amino-Functionalized IBN-4 
Post-synthetic modification was carried out by adding 0.2 g of the IBN-4 solids in 30 mL of toluene 
and stirring the reaction mixture. A 0.3 mL aliquot of a pure APTS solution was added to the mixture 
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and allowed to stir at 100 °C for 20 h. The amino-functionalized particles were collected by 
centrifugation at 12,000 rpm for 17 min and were washed twice using acetone and ethanol. 
3.5. Detection of Primary Amines with a Ninhydrin Test 
The procedure employed methods following a previously published report on the detection of  
amine-functionalized silica material [77]. Typically, 50 mg of the samples was mixed with 5 mL of 
ethanolic ninhydrin solution (0.2 M). The solution was stirred at room temperature for 25 min. 
Subsequently, the supernatant was collected to and centrifuged for 10 min. The absorbance of the 
supernatant was monitored at 580 nm by UV-Vis spectrometry. 
3.6. Covalent Immobilization of HRP onto IBN-4 Materials (IBN-4-HRP) 
Enzymes were immobilized onto IBN-4 nanomaterials following a previously published  
method [78]. Initially, 0.15 g of amine-functionalized particles was dispersed in 22.5 mL of a 0.1 M  
Na2HPO4-NaH2PO4 buffer solution (pH 8.0) through ultra-sonication. A 50% glutaraldehyde (GA) 
solution was added to the particles dispersed in buffer to reach a final volume of 0.1% (v/v). The 
reaction mixture was continuously stirred for one hour at room temperature and the GA-modified 
particles were collected by centrifugation. Later, the HRP buffer solution was prepared by dissolving 
22.5 mg of HRP in 15 mL of a 10 mM Na2HPO4-NaH2PO4 buffer solution (pH 8.0). Finally, 0.15 g of 
the GA-modified IBN-4 particles was redispersed in the HRP buffer solution by ultra-sonication. The 
reaction mixture was then stirred at 10 °C for 2 h and collected by centrifugation. The unbound 
enzymes were removed by washing them once with a 10 mM Na2HPO4-NaH2PO4 buffer solution. The 
enzyme-bound particles were redispersed in 15 mL of a 10 mM Na2HPO4-NaH2PO4 buffer solution 
(pH-8.0) and stored at 4 °C. 
3.7. Covalent Immobilization of HRP into IBN-4 Materials by One pot Process (IBN-4-HRP  
(One Pot)) 
The direct method of HRP immobilization onto IBN-4 nanomaterials followed a previously 
published method [79]. At first, 10 mg of amino-functionalized particles was dispersed in 5 mL of a 
phosphate buffer saline (PBS) solution (pH 7.4) by ultrasonic dispersion and was followed by the 
addition of 5 mL of a 2.5% glutaraldehyde solution. The reaction mixture was stirred for 2 h at room 
temperature and then 5 mg of HRP was added. The reaction mixture was allowed to stir at 4 °C for  
24 h and the particles were recovered by centrifugation. The unbound enzymes were removed by 
washing them with PBS. Finally, the enzyme-conjugated particles were redispersed in 1 mL of pH 7.4 
PBS and stored at 4 °C. 
3.8. HRP Enzymatic Assay 
The peroxidase activity of HRP was measured colorimetrically. The principle behind this 
measurement involves the peroxidation of pyrogallol to purpurogallin in the presence of HRP. A 
reaction mixture (3.00 mL) was prepared to contain the following final concentrations: 100 mM 
potassium phosphate buffer (pH-6.0), 0.5% (w/w) hydrogen peroxide, 5.0% (w/v) pyrogallol, and  
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IBN-4-HRP (1 mg/mL). The reaction was allowed to continue for 5 min while the contents were mixed 
properly. The absorbance was measured at 420 nm with a UV-Vis spectrophotometer through 
calibration for 10 min at 30 °C. The absorbance of a blank sample was obtained using water. One unit/g of 
the IBN-4-HRP formed 1.0 mg of purpurogallin from pyrogallol at specific pH and temperatures. All 
the activity measurements were performed in triplicate. 
3.9. Cytotoxicity Studies 
Cell Culture: a HT-29 (colon carcinoma) cell line was cultured in Roswell Park Memorial Institute 
(RPMI)-1640 medium supplemented with 10% (v/v) fetal bovine serum (FBS). Cultures were 
maintained in a humidified incubator at 37 °C with 5% CO2 (carbon dioxide). Cell viability studies of 
the prepared particles were evaluated in vitro using a standard MTT (3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide) colorimetric assay. HT-29 cells were seeded in 96-well plates at a 
density of 1 × 104 cells per well. After letting the cells adhere overnight, the cells were serum-starved 
in RPMI-1640 medium. The cells were incubated for 24 h and then treated with various concentrations 
(0.5–1000 µM) of 3-indoleacetic acid and enzyme-conjugated nanoparticles (0.1 mg/mL) and were 
incubated for another 24 h. Subsequently, 50 µL of an MTT solution (1 mg of MTT in 1 mL of PBS) 
was added and incubation was continued for another 4 h. The relative percentages of metabolically 
active cells relative to the untreated control cells were then determined based on the mitochondrial 
conversion of MTT to formazan. Finally, the medium was pipetted out and 150 μL of DMSO was 
added to wells to dissolve the crystals; then, the absorbances of the individual wells were measured 
with a Microplate Reader at 570 nm. 
3.10. LDH Release Assay 
HT-29 cells (1 × 105 cells/well) were seeded in a 12-well plate. The cells were grown in 10%  
FBS-supplemented RPMI-1640. The cultured cells were treated with various sample combinations 
using IAA and IBN-4-HRP and were incubated for another 24 h. The levels of cytosolic LDH (lactate 
dehydrogenase) leakage were assessed to measure the extent of cellular membrane damage using  
a Sigma Tox-7 Kit (Sigma-Aldrich®, St Louis, MO, USA) following the manufacturer’s instructions. 
This kit spectrophotometrically determines LDH activity by measuring the intensity of the reduced 
formazan at 490 nm, which is directly proportional to the LDH activity. These measurements were 
performed with an ELISA reader. The results presented represent mean values from triplicate 
measurements. The results are given as fractions of LDH release compared to the positive controls, 
which consisted of 0.5% Triton X-100 (yielding 100% LDH release). 
3.11. Comet Assay 
The DNA comet assay was performed using a Trevigen’s Comet Assay® kit (Trevigen, Inc. 
Gaithersburg, MD, USA) according to the manufacturer’s instructions. HT-29 cells were seeded at a 
density of 1 × 105 cells/well in a 6-well plate and various treatments were performed. The plates were 
placed in an incubator for 20 h. After harvesting, the cells were pooled in a 1% low melting point 
agarose gel at a ratio of 1:10 (v/v). The gel was run in accordance with the manufacturers’ instructions 
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for 20 min at 21 volts and 350 mA. The gel was then washed with water and ethanol to reanneal the 
DNA; eventually, the smear was stained with SYBR Green. DNA comets were considered to be 
markers of genotoxic effects. The images were captured using Olympus fluorescence image analyses. 
4. Conclusions 
To improve the enzymatic activity and stability of nanoparticles for use in therapeutic applications, 
the fragile enzyme molecules required immobilization on solid supports to prevent degradation and 
unfolding of the proteins. In this study, we immobilized an HRP enzyme onto nanochannels of 
mesoporous silica nanoparticles to demonstrate their ability to activate an anticancer prodrug  
(indole-3-acetic acid). The immobilization of HRP and activity experiments indicated that the confined 
spaces in mesoporous silica could maintain HRP microenvironments and therapeutic activities. The large 
pores of the mesoporous silica (IBN-4) nanocontainers were suitable for immobilizing HRP enzymes 
through covalent bonds. The conditions employed for enzyme loading using a typical approach via two 
chemical steps generated more favorable critical parameters for enzyme orientation and specific 
activities than the one-pot approach. It is expected that IBN-4 materials with large surface areas, pore 
sizes, and high biocompatibility can be used to enhance the stability of HRP enzymes and increase the 
diffusion rates of catalytic substrates, which can be used in EPT for cancer therapeutic applications. 
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